AR039203A1 - Derivados de quinazolina - Google Patents

Derivados de quinazolina

Info

Publication number
AR039203A1
AR039203A1 ARP030101122A ARP030101122A AR039203A1 AR 039203 A1 AR039203 A1 AR 039203A1 AR P030101122 A ARP030101122 A AR P030101122A AR P030101122 A ARP030101122 A AR P030101122A AR 039203 A1 AR039203 A1 AR 039203A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally
alkoxy
hydroxy
halogen
Prior art date
Application number
ARP030101122A
Other languages
English (en)
Spanish (es)
Inventor
Robert Bradbury
Laurent Hennequin
Jason Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039203(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0207323A external-priority patent/GB0207323D0/en
Priority claimed from GB0230086A external-priority patent/GB0230086D0/en
Priority claimed from GB0301916A external-priority patent/GB0301916D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR039203A1 publication Critical patent/AR039203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP030101122A 2002-03-28 2003-03-28 Derivados de quinazolina AR039203A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207323A GB0207323D0 (en) 2002-03-28 2002-03-28 Compounds
GB0230086A GB0230086D0 (en) 2002-12-24 2002-12-24 Compounds
GB0301916A GB0301916D0 (en) 2003-01-28 2003-01-28 Compounds

Publications (1)

Publication Number Publication Date
AR039203A1 true AR039203A1 (es) 2005-02-09

Family

ID=28678580

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101122A AR039203A1 (es) 2002-03-28 2003-03-28 Derivados de quinazolina

Country Status (28)

Country Link
US (4) US20050215574A1 (enExample)
EP (1) EP1487806B1 (enExample)
JP (2) JP3891493B2 (enExample)
KR (1) KR101006947B1 (enExample)
CN (1) CN100439344C (enExample)
AR (1) AR039203A1 (enExample)
AT (1) ATE473215T1 (enExample)
AU (1) AU2003214443B8 (enExample)
BR (1) BR0308670A (enExample)
CA (1) CA2479642C (enExample)
CY (1) CY1111039T1 (enExample)
DE (1) DE60333262D1 (enExample)
DK (1) DK1487806T3 (enExample)
ES (1) ES2346135T3 (enExample)
IL (2) IL164135A0 (enExample)
IS (1) IS2855B (enExample)
MX (1) MXPA04009486A (enExample)
MY (1) MY158054A (enExample)
NO (1) NO329542B1 (enExample)
NZ (1) NZ535014A (enExample)
PL (1) PL214880B1 (enExample)
PT (1) PT1487806E (enExample)
SA (1) SA03240080B1 (enExample)
SI (1) SI1487806T1 (enExample)
TW (2) TW200813014A (enExample)
UA (1) UA78302C2 (enExample)
UY (1) UY27742A1 (enExample)
WO (1) WO2003082831A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287010B6 (sk) * 1999-06-21 2009-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
ATE423104T1 (de) * 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
JP4492849B2 (ja) * 2001-11-19 2010-06-30 インターリューキン ジェネティックス インコーポレイテッド 転写および炎症性疾患および感染症に対する感受性に影響するインターロイキン−１遺伝子座の機能的多型
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PL371188A1 (en) * 2002-03-30 2005-06-13 Boehringer Ingelheim Pharma Gmbh & Co.Kg 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
KR20060054388A (ko) * 2003-07-29 2006-05-22 아스트라제네카 아베 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2005026151A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DK1667991T3 (da) * 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
CA2539049A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
DE602004004553T2 (de) * 2003-09-19 2007-10-25 Astrazeneca Ab Chinazolinderivate
EP1670782B1 (en) * 2003-09-19 2007-02-14 AstraZeneca AB Quinazoline derivatives
EP1670786A1 (en) * 2003-09-25 2006-06-21 Astrazeneca AB Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005044302A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
CA2567832A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases
DE602005026865D1 (de) * 2004-12-14 2011-04-21 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
ATE521603T1 (de) * 2005-02-26 2011-09-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
EP1919900A2 (de) * 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1928861B1 (en) * 2005-09-20 2010-11-17 AstraZeneca AB 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
EP1940825A1 (en) * 2005-09-20 2008-07-09 Astra Zeneca AB Quinazoline derivatives as anticancer agents
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
EP1960371B1 (en) * 2005-12-02 2009-09-16 AstraZeneca AB Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
JP2009517450A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ チロシンキナーゼ阻害薬としての４−アニリノ置換キナゾリン誘導体
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
CA2663599A1 (en) * 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
AU2009247782C1 (en) * 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
EP2313377B1 (de) 2008-08-08 2016-01-06 Boehringer Ingelheim International Gmbh Verfahren zur stereoselektiven synthese bicyclischer heterocyclen
CA2733153C (en) * 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
AU2010240717A1 (en) 2009-04-23 2011-10-27 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PE20141012A1 (es) 2011-02-01 2014-09-10 Boehringer Ingelheim Int Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
EP2680850B1 (en) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
WO2013143057A1 (zh) 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 喹唑啉衍生物及用途
CN102659692B (zh) 2012-05-04 2014-04-09 郑州泰基鸿诺药物科技有限公司 双联厄洛替尼及其制备方法
WO2014012859A1 (en) 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
MY186126A (en) 2013-03-06 2021-06-24 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN104530063B (zh) * 2015-01-13 2017-01-18 北京赛特明强医药科技有限公司 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
UY37935A (es) * 2017-10-18 2020-03-31 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616582A (en) * 1950-11-28 1952-11-04 Whitney Kappes Co Bung
IT1019480B (it) * 1973-10-27 1977-11-10 Deutsche Automobilgesellsch Perfezionamento negli elettrodi di zinco picaricabili
US3985749A (en) * 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4456359A (en) 1981-11-04 1984-06-26 Ciba-Geigy Ag Flat photographic sheet processing cassette
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU1721697A (en) * 1996-01-31 1997-08-22 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
US6262054B1 (en) 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
GB9626589D0 (en) 1996-12-20 1997-02-05 Prolifix Ltd Peptides
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
JP4245682B2 (ja) 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CZ20013079A3 (cs) * 1999-02-27 2001-11-14 Boehringer Ingelheim Pharma Kg Deriváty 4-aminochinazolinu a chinolinu
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
WO2000068203A1 (en) * 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
SK287010B6 (sk) * 1999-06-21 2009-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
NL1014401C2 (nl) * 2000-02-17 2001-09-04 Stichting Tech Wetenschapp Ceriumhoudend anorganisch scintillatormateriaal.
WO2001076630A1 (en) 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for rheumatoid arthritis
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
BR0113358A (pt) * 2000-08-21 2003-07-01 Astrazeneca Ab Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
EP1350793A1 (en) 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
ATE475652T1 (de) 2001-02-21 2010-08-15 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP2003246780A (ja) 2001-12-17 2003-09-02 Eisai Co Ltd 含窒素芳香環化合物の製造方法
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1481971B1 (en) 2002-02-06 2011-11-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) * 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
CN1192564C (zh) 2002-06-06 2005-03-09 华为技术有限公司 开放最短路径优先协议第五类链路状态通告分组刷新的方法
AT6168U1 (de) 2002-07-15 2003-05-26 Blum Gmbh Julius Scharnier
CN1688549A (zh) 2002-08-23 2005-10-26 麒麟麦酒株式会社 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物
WO2004060400A1 (ja) 2003-01-06 2004-07-22 Mitsubishi Pharma Corp 上皮成長因子受容体を分子標的とする抗精神病薬
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
DE10300097A1 (de) 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
KR20060054388A (ko) * 2003-07-29 2006-05-22 아스트라제네카 아베 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DE602004004553T2 (de) 2003-09-19 2007-10-25 Astrazeneca Ab Chinazolinderivate
EP1670782B1 (en) * 2003-09-19 2007-02-14 AstraZeneca AB Quinazoline derivatives
EP1670786A1 (en) * 2003-09-25 2006-06-21 Astrazeneca AB Quinazoline derivatives
SE526965C2 (sv) * 2005-01-24 2005-11-29 Jan Hansen Anordning vid minigolfspel
KR20080028813A (ko) 2006-09-27 2008-04-01 삼성전자주식회사 통신 시스템에서 파일럿 채널 탐색 제어 장치 및 방법

Also Published As

Publication number Publication date
EP1487806A1 (en) 2004-12-22
TW200403227A (en) 2004-03-01
JP2006249093A (ja) 2006-09-21
UY27742A1 (es) 2003-10-31
CA2479642A1 (en) 2003-10-09
SI1487806T1 (sl) 2010-09-30
AU2003214443A1 (en) 2003-10-13
TWI324597B (en) 2010-05-11
NZ535014A (en) 2007-07-27
IS7469A (is) 2004-09-24
US8399667B2 (en) 2013-03-19
MXPA04009486A (es) 2005-01-25
TW200813014A (en) 2008-03-16
US20130005727A1 (en) 2013-01-03
EP1487806B1 (en) 2010-07-07
UA78302C2 (uk) 2007-03-15
JP2005529092A (ja) 2005-09-29
SA03240080B1 (ar) 2009-04-20
IL164135A0 (en) 2005-12-18
HK1070888A1 (en) 2005-06-30
CN1656081A (zh) 2005-08-17
ES2346135T3 (es) 2010-10-11
PL372889A1 (en) 2005-08-08
PL214880B1 (pl) 2013-09-30
NO329542B1 (no) 2010-11-08
CA2479642C (en) 2010-06-08
AU2003214443B8 (en) 2009-08-20
AU2003214443B2 (en) 2009-07-16
DE60333262D1 (en) 2010-08-19
NO20044325L (no) 2004-12-16
PT1487806E (pt) 2010-08-27
KR101006947B1 (ko) 2011-01-12
US20080269487A1 (en) 2008-10-30
DK1487806T3 (da) 2010-09-20
IL164135A (en) 2011-07-31
JP3891493B2 (ja) 2007-03-14
HK1079521A1 (zh) 2006-04-07
US20100152442A1 (en) 2010-06-17
ATE473215T1 (de) 2010-07-15
MY158054A (en) 2016-08-30
CY1111039T1 (el) 2015-06-11
CN100439344C (zh) 2008-12-03
BR0308670A (pt) 2005-02-01
US20050215574A1 (en) 2005-09-29
KR20040094891A (ko) 2004-11-10
IS2855B (is) 2013-11-15
WO2003082831A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
AR039203A1 (es) Derivados de quinazolina
AR049294A1 (es) DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS.
AR045762A1 (es) Derivados de quinazolina
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR054612A1 (es) Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
SG154435A1 (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
NZ596304A (en) Substituted aminopropionic derivatives as neprilysin inhibitors
AR045752A1 (es) Derivados de quinazolina que poseen actividad antitumoral
EP2168581A3 (en) Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
AR046308A1 (es) Derivados amida
RU2009113615A (ru) Ингибитор киназы
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
TW200621249A (en) Substituted amide beta secretase inhibitors
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
HRP20141116T1 (hr) 1h-kinazolin-2,4-dioni
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
ATE428427T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR045694A1 (es) Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
US20060235006A1 (en) Combinations, methods and compositions for treating cancer
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase

Legal Events

Date Code Title Description
FG Grant, registration